Literature DB >> 9601125

The discovery, development and clinical applications of granulocyte colony-stimulating factor.

D C Dale1.   

Abstract

The story of the discovery, development and applications of G-CSF illustrates many of the best features of modern laboratory and clinical investigation. The initial discovery of the CSFs was somewhat serendipitous. The pathway to understanding the cellular and molecular base for the action of these substances was long, but fruitful and exciting for those who pursued it tirelessly. The power of modern molecular biology is illustrated by the rapid advances which followed the cloning of the G-CSF gene. Major advances in our understanding of the regulation of neutrophil production and deployment have followed, together with many important clinical observations. To date hundreds of thousands of patients have been treated with G-CSF and some individuals with severe chronic neutropenia have received daily therapy for more than ten years. Results of recent studies suggest that there will be many more interesting and important clinical applications for G-CSF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9601125      PMCID: PMC2194342     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  45 in total

Review 1.  Filgrastim (r-metHuG-CSF): the first 10 years.

Authors:  K Welte; J Gabrilove; M H Bronchud; E Platzer; G Morstyn
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

Review 2.  Review: granulocyte colony-stimulating factor--role and relationships in infectious diseases.

Authors:  D C Dale; W C Liles; W R Summer; S Nelson
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

3.  Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils.

Authors:  W C Liles; P A Kiener; J A Ledbetter; A Aruffo; S J Klebanoff
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

4.  Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans.

Authors:  T H Price; G S Chatta; D C Dale
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

Review 5.  Pathophysiology and treatment of severe chronic neutropenia.

Authors:  K Welte; D Dale
Journal:  Ann Hematol       Date:  1996-04       Impact factor: 3.673

6.  Effect of endotoxin on serum granulocyte and granulocyte-macrophage colony-stimulating factor levels in dogs.

Authors:  D C Dale; S Lau; R Nash; T Boone; W Osborne
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

7.  An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy.

Authors:  C H Weaver; B Hazelton; R Birch; P Palmer; C Allen; L Schwartzberg; W West
Journal:  Blood       Date:  1995-11-15       Impact factor: 22.113

8.  Differential alterations in plasma colony-stimulating factor concentrations in meningococcaemia.

Authors:  P M Waring; J Presneill; D W Maher; J E Layton; J Cebon; L J Waring; D Metcalf
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

9.  Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis.

Authors:  H Tanaka; K Ishikawa; M Nishino; T Shimazu; T Yoshioka
Journal:  J Trauma       Date:  1996-05

10.  Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization.

Authors:  G J Lieschke; D Grail; G Hodgson; D Metcalf; E Stanley; C Cheers; K J Fowler; S Basu; Y F Zhan; A R Dunn
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

View more
  2 in total

Review 1.  Congenital neutropenia: diagnosis, molecular bases and patient management.

Authors:  Jean Donadieu; Odile Fenneteau; Blandine Beaupain; Nizar Mahlaoui; Christine Bellanné Chantelot
Journal:  Orphanet J Rare Dis       Date:  2011-05-19       Impact factor: 4.123

Review 2.  Toward a universal treatment for cancer: cell inflation assisted chemotherapy.

Authors:  Daniel Corcos
Journal:  Cancer Med       Date:  2013-05-28       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.